Article Text

THU0032 Fibromyalgia Prevalence and Related Factors in A Large Spanish Cohort of Patients with Systemic Lupus Erythematosus
  1. T. Salman-Monte1,
  2. V. Torrente-Segarra2,
  3. I. Rúa-Figueroa3,
  4. J. Pego-Reigosa4,
  5. F. Lόpez-Longo5,
  6. M. Galindo6,
  7. J. Calvo-Alén7,
  8. S. Pérez Vicente8
  9. on behalf of RELESSER Study Group of the Spanish Society of Rheumatology
  1. 1Rheumatology, Parc de Salut Mar/IMIM, Barcelona
  2. 2Rheumatology, Hospital General Hospitalet-HSJDMoisès Broggi, Hospitalet Llobregat
  3. 3Rheumatology, Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria
  4. 4Rheumatology, Hospital do Meixoeiro, Vigo
  5. 5Rheumatology, Hospital Gregorio Marañόn
  6. 6Rheumatology, Instituto de Investigaciόn Hospital 12 de Octubre (I+12), Madrid
  7. 7Rheumatology, Hospital Sierrallana, Torrelavega
  8. 8Research Unit SER, Spanish Society of Rheumatology, Spain


Background Systemic lupus erythematosus (SLE) is an autoimmune disease that may affect multiple organs. Fibromyalgia (FM) is a physical, mental and social impairing disease. FM has been observed in SLE patients. The objective of this study is to determine the prevalence of FM in SLE patients, and to study its association to depression and other SLE-related factors. As has been previously described, FM looks to be more frequent in long-term SLE than in early SLE stages.

Methods A cross-sectional data analysis from RELESSER-T Spanish registry, which includes SLE patients in a National multicenter retrospective charts review. Inclusion criteria: SLE patients who fulfilled ≥4 ACR-SLE diagnostic criteria. We divided them into 2 groups: ≤5 years of SLE duration, and >5 years of SLE duration. Main variables were FM. Depression, sociodemographics, comorbidities, active SLE symptoms, serological markers, therapies and different indexes to assess the status of the disease. Descriptive, associative and logistic regression statistical analyses were performed.

Results We selected 3,679 SLE patients. A total of 3,229 (90.1%) were women, with a mean age at the time of diagnosis of 34.6 (SD 14.6) years old. A total of 93.1% were Caucasians. FM prevalence was 6.2%, being higher in those with SLE duration longer than five years (6.9% vs 4%) (p<0,05). SLE-FM patients showed higher prevalence of Depression (53.1% vs 14.6%) (p<0,05). Adjusting by risk factors: comorbidities, age, SLE disease duration time and mean highest steroids dosage, the risk of suffering depression in FM-SLE patients is 7.295 (CI 5.180-10.274) (p<0,05). FM in SLE was inversely associated to the presence of several clinical symptoms, serological markers and activity index scores (Table 1).

Table 1.

Multivariate logistic regression analyses

Conclusions FM in Caucasian SLE patients was significantly higher in patients with longer disease duration and in older women. The presence of FM in both groups was strongly associated to the presence of Depression, which showed a 7.2 fold risk association. The main SLE-related related factors were longer disease duration and steroids mean highest daily dosage range 10-30 mg. All this information might help to a better comprehension and therapeutic approach of FM in patients with SLE.

Disclosure of Interest : None declared

DOI 10.1136/annrheumdis-2014-eular.2046

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.